A prospective study to evaluate the immune responses of UK infants to their routine 12-month booster vaccines fol-lowing receipt of different meningococcal capsular group C (MenC) conjugate vaccines as part of their primary immunisation schedule (code: P13BOOST)

Trial Profile

A prospective study to evaluate the immune responses of UK infants to their routine 12-month booster vaccines fol-lowing receipt of different meningococcal capsular group C (MenC) conjugate vaccines as part of their primary immunisation schedule (code: P13BOOST)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Haemophilus meningitis; Measles; Meningococcal group C infections; Mumps; Pneumococcal infections; Rubella
  • Focus Pharmacodynamics
  • Acronyms P13Boost
  • Most Recent Events

    • 06 Sep 2013 Status changed from completed to discontinued as reported by United Kingdom Clinical Research Network.
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 28 Apr 2013 Planned End Date changed from 1 Aug 2013 to 1 Jun 2014 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top